MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
AstraZeneca PLC (NASDAQ:AZN)*
Finance & Acquisition: AstraZeneca
EsoBiotec SA
Organization & Developments: EsoBiotec
Parents
EsoBiotec SA
Children
* By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases. EsoBiotec’s proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, eliminate the need for immune cell depletion and have the potential to improve efficacy and safety through advanced lentiviral vector technology.
* The vector has modifications which deliver specificity to immune cells, such as T cells, and also enable the vector to evade rapid elimination by the patient’s immune system.
*Empowering Cells In Vivo to Fight Cancer
*ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases
*EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer cell therapy treatments delivered in just minutes rather than the current process which takes weeks
*EsoBiotec is a leading in vivo cell therapy company with the mission to make these innovative treatments more accessible, effective and affordable.
*EsoBiotec’s proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, eliminate the need for immune cell depletion and have the potential to improve efficacy and safety through advanced lentiviral vector technology.
*First Patient With Multiple Myeloma Dosed in EsoBiotec's Trial for In Vivo CAR-T ESO-T01
2025: EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
Jumps
Finance & Acquisition: EsoBiotec
Key People: EsoBiotec